Spyre Therapeutics (NASDAQ:SYRE) Cut to "Peer Perform" at Wolfe ResearchMarket Beat·4 hours agoSYRE-1.80%
Spyre Therapeutics (NASDAQ:SYRE) Stock Price Expected to Rise, Mizuho Analyst SaysMarket Beat·Jul 13 at 07:06 AMSYRE-1.80%
Spyre Therapeutics CEO Cameron Turtle sells common shares worth $1.32 millionPUBT·Jul 2 at 08:32 PMSYRE-1.80%
Spyre Therapeutics grants inducement equity awards of 58,843 stock options, 2,134 RSUs to new hiresPUBT·Jul 2 at 03:06 PMSYRE-1.80%
Will Spyre’s US$500 Million ATM and Russell Exit Change Spyre Therapeutics' (SYRE) NarrativeSimplywall·Jul 2 at 10:51 AMSYRE-1.80%
Spyre Therapeutics CFO Scott Burrows disposes of common shares worth $1.31 millionPUBT·Jun 26 at 08:32 PMSYRE-1.80%
What's Going On With Spyre Therapeutics Stock On Wednesday?benzinga_article·Jun 24 at 10:56 AMSYRE-1.80%
Micron, FedEx And 3 Stocks To Watch Heading Into Wednesdaybenzinga_article·Jun 24 at 12:13 AMFDX+0.33%JEF+1.80%
Spyre Therapeutics director Michael Thomas Henderson disposes of 20,000 common shares for $2 millionPUBT·Jun 23 at 08:33 PMSYRE-1.80%
